Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial
Sánchez-Lara K, Turcott JG, Juárez-Hernández E, Nuñez-Valencia C, Villanueva G, Guevara P, De la Torre-Vallejo M, Mohar A, Arrieta O
Clinical nutrition (Edinburgh, Scotland) · 171 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Consejo Nacional de Ciencia y Tecnología
- Gobierno
- National Institutes of Health
- Gobierno
- National Cancer Institute
- Gobierno
- National Council of Science and Technology of Mexico
Según 4 financiadores declarados.
Publicación
- Publicado
- 2014-04-04 · Clin Nutr · vol. 33 · número 6 · págs. 1017–1023
- Editorial
- Elsevier BV
- Citado
- 242 citas · más que el 99% de estudios similares · 11.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 29 trabajos
- Acceso
- De pago
- Áreas de investigación
- Clinical Nutrition and Gastroenterology · Nutrition and Health in Aging · Lung Cancer Diagnosis and Treatment
- Palabras clave
- eicosapentaenoic acid, oral nutritional supplements, non-small cell lung cancer, advanced cancer, nutritional support, lean body mass, body composition, energy and protein intake, fatigue, appetite loss, chemotherapy-induced peripheral neuropathy, inflammatory parameters, health-related quality of life, paclitaxel, cisplatin, carboplatin
- MeSH
- humans, carcinoma, non-small-cell lung, body weight, cisplatin, carboplatin, eicosapentaenoic acid, prognosis, treatment outcome, administration, oral, appetite, body composition, energy intake, nutritional status, quality of life, dietary supplements, adolescent, adult, aged, aged, 80 and over, middle aged, female, male, young adult
9 autores
- Karla Sánchez-Lara🇲🇽Instituto Nacional de Cancerología
- Jenny Georgina Turcott🇲🇽Instituto Nacional de Cancerología
- Eva Juárez-Hernández🇲🇽Instituto Nacional de Cancerología
- Carolina Núñez-Valencia🇲🇽Instituto Nacional de Cancerología
- Geraldine Villanueva🇲🇽Instituto Nacional de Cancerología
- Patricia Guevara‐Ramírez🇲🇽Instituto Nacional de Neurología y Neurocirugía
- Martha De la Torre-Vallejo🇲🇽Instituto Nacional de Cancerología
- Alejandro Mohar🇲🇽Instituto Nacional de Cancerología
- Oscar G. Arrieta🇲🇽 · autor de correspondenciaInstituto Nacional de Cancerología; Universidad Nacional Autónoma de México
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects.
Objective
To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients.
Design
Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated.
Results
Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups.
Conclusion
Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.